NO20002162L - Tienopyrimidin- og tienopyridinderivater nyttige som anticancer midler - Google Patents

Tienopyrimidin- og tienopyridinderivater nyttige som anticancer midler

Info

Publication number
NO20002162L
NO20002162L NO20002162A NO20002162A NO20002162L NO 20002162 L NO20002162 L NO 20002162L NO 20002162 A NO20002162 A NO 20002162A NO 20002162 A NO20002162 A NO 20002162A NO 20002162 L NO20002162 L NO 20002162L
Authority
NO
Norway
Prior art keywords
tienopyrimidine
anticancer agents
derivatives useful
thienopyridine derivatives
thienopyridine
Prior art date
Application number
NO20002162A
Other languages
English (en)
Norwegian (no)
Other versions
NO20002162D0 (no
Inventor
Michael John Munchhof
Susan Beth Sobolov-Jaynes
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20002162D0 publication Critical patent/NO20002162D0/no
Publication of NO20002162L publication Critical patent/NO20002162L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20002162A 1997-11-11 2000-04-27 Tienopyrimidin- og tienopyridinderivater nyttige som anticancer midler NO20002162L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6509797P 1997-11-11 1997-11-11
PCT/IB1998/001691 WO1999024440A1 (en) 1997-11-11 1998-10-22 Thienopyrimidine and thienopyridine derivatives useful as anticancer agents

Publications (2)

Publication Number Publication Date
NO20002162D0 NO20002162D0 (no) 2000-04-27
NO20002162L true NO20002162L (no) 2000-07-10

Family

ID=22060322

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002162A NO20002162L (no) 1997-11-11 2000-04-27 Tienopyrimidin- og tienopyridinderivater nyttige som anticancer midler

Country Status (37)

Country Link
US (1) US6492383B1 (is)
EP (1) EP1028964A1 (is)
JP (1) JP2001522853A (is)
KR (1) KR100446363B1 (is)
CN (2) CN101328186A (is)
AP (1) AP976A (is)
AR (1) AR018517A1 (is)
AU (1) AU9454198A (is)
BG (1) BG65180B1 (is)
BR (1) BR9814018A (is)
CA (1) CA2309690A1 (is)
CO (1) CO4990956A1 (is)
CZ (1) CZ20001709A3 (is)
DZ (1) DZ2646A1 (is)
EA (1) EA005889B1 (is)
GT (1) GT199800180A (is)
HN (1) HN1998000168A (is)
HR (1) HRP20000286A2 (is)
HU (1) HUP0100287A3 (is)
ID (1) ID23978A (is)
IL (1) IL135636A0 (is)
IS (1) IS5464A (is)
MA (1) MA24694A1 (is)
MY (1) MY132073A (is)
NO (1) NO20002162L (is)
NZ (1) NZ520093A (is)
OA (1) OA11376A (is)
PA (1) PA8462401A1 (is)
PE (1) PE129099A1 (is)
PL (1) PL340589A1 (is)
SK (1) SK6652000A3 (is)
TN (1) TNSN98203A1 (is)
TW (1) TW593321B (is)
UA (1) UA72881C2 (is)
UY (2) UY25238A1 (is)
WO (1) WO1999024440A1 (is)
ZA (1) ZA9810253B (is)

Families Citing this family (195)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE368665T1 (de) 1997-08-22 2007-08-15 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
EP1006113A1 (en) 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
GB9918057D0 (en) * 1999-07-30 1999-10-06 Univ Bristol Therapeutic agents
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
GB0010757D0 (en) * 2000-05-05 2000-06-28 Astrazeneca Ab Chemical compounds
TR200402656T4 (tr) * 2000-06-06 2004-11-22 Pfizer Products Inc. Antikanser ajanları olarak faydalı tiyofen türevleri
WO2002012227A2 (en) * 2000-08-09 2002-02-14 Astrazeneca Ab Indole, azaindole and indazole derivatives having vegf inhibiting activity
US7547702B2 (en) 2000-09-20 2009-06-16 Ortho-Mcneil Pharmaceutical, Inc. 4-amino-quinazolines
US6503914B1 (en) * 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
AUPR213700A0 (en) 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
KR20020051675A (ko) * 2000-12-23 2002-06-29 이상남 4-페닐아미노티에노 [3,2-디] 피리미딘 유도체 및 이의제조방법
EP2796468A2 (en) 2001-01-05 2014-10-29 Pfizer Inc Antibodies to insulin-like growth factor I receptor
ATE330956T1 (de) * 2001-04-13 2006-07-15 Pfizer Prod Inc Bizyklisch substituierte 4- aminopyridopyrimidinderivate
US6995171B2 (en) 2001-06-21 2006-02-07 Agouron Pharmaceuticals, Inc. Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents
US7829566B2 (en) 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
WO2003053446A1 (en) * 2001-12-19 2003-07-03 Smithkline Beecham Corporation Thienopyrimidine compounds as protein tyrosine kinase inhibitors
WO2003055890A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
CA2472619A1 (en) 2002-01-10 2003-07-24 Bayer Corporation Fused pyrimidine derivates as rho-kinase inhibitors
MXPA04007191A (es) 2002-01-23 2005-03-31 Bayer Pharmaceuticals Corp Derivados de pirimidina como inhibidores de rho-quinasa.
MXPA04007196A (es) 2002-01-23 2005-06-08 Bayer Pharmaceuticals Corp Inhibidores de rho-quinasa.
WO2003064428A1 (en) * 2002-01-29 2003-08-07 H. Lundbeck A/S Furano- and thienopyrimidines as neurokinase inhibitors
WO2003070241A1 (en) * 2002-02-15 2003-08-28 Rigel Pharmaceuticals, Inc. Inhibitors of tubulin polymerization
US20030225273A1 (en) * 2002-03-21 2003-12-04 Michaelides Michael R. Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
UA77303C2 (en) * 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
DE60304718T2 (de) 2002-08-06 2007-04-26 Astrazeneca Ab Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
TWI335913B (en) * 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
US7276519B2 (en) * 2002-11-25 2007-10-02 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
CL2003002287A1 (es) * 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
PL377713A1 (pl) 2002-12-19 2006-02-06 Pfizer Inc. Związki 2-(1H-indazol-6-iloamino)benzamidowe jako inhibitory kinaz białkowych użyteczne w leczeniu chorób oczu
CA2529611C (en) 2002-12-20 2009-12-15 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
GEP20084341B (en) 2003-02-26 2008-03-25 Sugen Inc Aminoheteroaryl compounds as protein kinase inhibitors
WO2005010008A1 (en) * 2003-07-24 2005-02-03 Bayer Pharmaceuticals Corporation Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
EP1663211B1 (en) * 2003-08-06 2010-01-20 Vertex Pharmaceuticals Incorporated Aminotriazole compounds useful as inhibitors of protein kinases
KR101028952B1 (ko) 2003-08-14 2011-04-12 어레이 바이오파마 인크. 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
EP1660504B1 (en) 2003-08-29 2008-10-29 Pfizer Inc. Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
US7332521B2 (en) * 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7419978B2 (en) 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
KR100807920B1 (ko) 2003-12-23 2008-02-27 화이자 인코포레이티드 신규한 퀴놀린 유도체
US7470712B2 (en) * 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
CA2553513A1 (en) * 2004-01-22 2005-08-04 Altana Pharma Ag N-4-(6- (heteo) aryl-pyrimidin-4-ylaminophenyl) -bezenesulfonamides as kinase inhibitors
BRPI0511512A (pt) * 2004-05-27 2007-12-26 Pfizer Prod Inc derivados pirrolpirimidina úteis no tratamento do cáncer
GB0412467D0 (en) * 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
US7173031B2 (en) * 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7879853B2 (en) 2004-06-28 2011-02-01 Bayer Schering Pharma Ag 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors
WO2006008639A1 (en) 2004-07-16 2006-01-26 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
ES2438017T3 (es) * 2004-07-30 2014-01-15 Methylgene Inc. Inhibidores de la señalización del receptor del VEGF y del receptor del HGF
BRPI0513915A (pt) 2004-08-26 2008-05-20 Pfizer compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
EP1804803A4 (en) * 2004-10-28 2008-07-30 Irm Llc COMPOUNDS AND COMPOSITIONS AS HEDGEHOG WALK MODULATORS
US7576080B2 (en) 2004-12-23 2009-08-18 Memory Pharmaceuticals Corporation Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors
AU2006207712A1 (en) * 2005-01-19 2006-07-27 F. Hoffmann-La Roche Ag 5-aminoindole derivatives
ATE477495T1 (de) 2005-03-16 2010-08-15 Osi Pharm Inc Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor
EP3300739A3 (en) 2005-03-31 2018-07-18 Agensys, Inc. Antibodies and related molecules that bind to 161p2f10b proteins
KR101203328B1 (ko) 2005-04-26 2012-11-20 화이자 인코포레이티드 Ｐ-카드헤린 항체
DK1904504T3 (da) 2005-05-20 2014-06-23 Methylgene Inc Inhibitorer af vegf-receptor- og hgf-receptorsignalering
NZ564283A (en) 2005-05-20 2011-07-29 Methylgene Inc Inhibitors of VEGF receptor and HGF receptor signaling
US20060281768A1 (en) * 2005-06-10 2006-12-14 Gaul Michael D Thienopyrimidine and thienopyridine kinase modulators
EP1899353A1 (en) * 2005-06-22 2008-03-19 DeveloGen Aktiengesellschaft Thienopyrimidines for pharmaceutical compositions
US7608592B2 (en) 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
WO2007026221A2 (en) * 2005-09-02 2007-03-08 Pfizer Inc. Improved methods for preparing benzofused heteroaryl amide derivatives of thienopyridines
HN2006031275A (es) 2005-09-07 2010-10-29 Amgen Fremont Inc Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
EP1926996B1 (en) 2005-09-20 2011-11-09 OSI Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
PE20070619A1 (es) * 2005-09-27 2007-07-02 Wyeth Corp TIENO(2,3-b)PIRIDIN-5-CARBONITRILOS COMO INHIBIDORES DE PROTEINAS QUINASA
US20070099877A1 (en) * 2005-11-02 2007-05-03 Cytovia, Inc. N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US20070099941A1 (en) * 2005-11-02 2007-05-03 Cytovia, Inc. N-arylalkyl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2007056214A2 (en) * 2005-11-02 2007-05-18 Cytovia, Inc N-alkyl-n-aryl-thienopyrimidin-r-amines and uses thereof
KR101086967B1 (ko) 2005-11-15 2011-11-29 어레이 바이오파마 인크. 과다증식성 질환의 치료를 위한 ｅｒｂｂ 유형 ｉ 수용체티로신 키나제 억제제로서의 ｎ4-페닐-퀴나졸린-4-아민유도체 및 관련 화합물
EP1989211A2 (en) * 2006-01-30 2008-11-12 Array Biopharma, Inc. Heterobicyclic thiophene compounds for the treatment of cancer
WO2007107005A1 (en) * 2006-03-22 2007-09-27 Methylgene, Inc. Inhibitors of protein tyrosine kinase activity
CN101437519A (zh) * 2006-03-31 2009-05-20 艾博特公司 吲唑化合物
CN101466716A (zh) * 2006-04-07 2009-06-24 德维洛根股份公司 用于药物组合物的具有mnkl/mnk2抑制活性的噻吩并嘧啶
EA200802058A1 (ru) 2006-05-09 2009-06-30 Пфайзер Продактс Инк. Производные циклоалкиламинокислот и их фармацевтические композиции
EP1889847A1 (en) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
WO2008058126A2 (en) 2006-11-06 2008-05-15 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
PE20081679A1 (es) 2006-12-07 2008-12-18 Hoffmann La Roche Compuestos del inhibidor de fosfoinositida 3-cinasa y metodos de uso
JP2010514810A (ja) * 2006-12-29 2010-05-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ａｘｌインヒビターとして有用な置換トリアゾール
WO2008082839A2 (en) * 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
WO2008086053A1 (en) * 2007-01-03 2008-07-17 Virobay, Inc. Hcv inhibitors
EP2158207B1 (en) * 2007-06-12 2011-05-25 F. Hoffmann-La Roche AG Thiazoliopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase
EP2014662A1 (de) * 2007-07-12 2009-01-14 Bayer Schering Pharma Aktiengesellschaft Indolylalkylthienopyrimidylamine als Modulatoren des EP2-Rezeptors
EP2014663A1 (de) * 2007-07-12 2009-01-14 Bayer Schering Pharma AG Thienopyrimidylamine als Modulatoren des EP2-Rezeptors
JP5736171B2 (ja) 2007-09-24 2015-06-17 ジェネンテック， インコーポレイテッド チアゾロピリミジンｐｉ３ｋ阻害剤化合物および使用方法
KR20100095528A (ko) * 2007-10-18 2010-08-31 베링거 인겔하임 인터내셔날 게엠베하 디하이드로티에노[3,2-ｄ]피리미딘의 제조방법 및 상기 제조방법에서 사용된 중간체
EP2214675B1 (en) 2007-10-25 2013-11-20 Genentech, Inc. Process for making thienopyrimidine compounds
US7956068B2 (en) * 2007-11-15 2011-06-07 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
MX2010005671A (es) * 2007-11-28 2010-06-25 Dana Farber Cancer Inst Inc Inhibidores de miristato de moleculas pequeñas contra bcr-abl y metodos de uso.
EP2229388A4 (en) * 2008-01-11 2012-03-07 Glenmark Pharmaceuticals Sa CONDENSED PYRIMIDINE DERIVATIVES AS TRPV3 MODULATORS
EA201001262A1 (ru) 2008-02-07 2011-04-29 Вайробей, Инк. Ингибиторы катепсина в
NZ588355A (en) 2008-03-05 2012-03-30 Methylgene Inc Inhibitors of protein tyrosine kinase activity
US8119647B2 (en) 2008-04-23 2012-02-21 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
AU2009286734A1 (en) 2008-08-26 2010-03-04 Boehringer Ingelheim International Gmbh Thienopyrimidines for pharmaceutical compositions
WO2010045495A2 (en) 2008-10-16 2010-04-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
KR101126736B1 (ko) * 2008-11-27 2012-04-12 주식회사 레고켐 바이오사이언스 티로신 키나아제 저해 화합물, 이의 이성질체 또는 이의 약학적으로 허용가능한 염 및 이를 포함하는 약학적 조성물
CA2748943A1 (en) 2009-02-09 2010-08-12 Supergen, Inc. Pyrrolopyrimidinyl axl kinase inhibitors
EP2400985A2 (en) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
JP2012519170A (ja) 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
WO2010098866A1 (en) 2009-02-27 2010-09-02 Supergen, Inc. Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
BRPI1006189A2 (pt) 2009-03-12 2020-08-18 Genentech Inc uso de uma combinação terapêutica, formulação farmacêutica, artigo de manufatura, produto, método para determinar compostos a serem utilizados em combinação para o tratamento de uma malignidade hematopoiética e método para selecionar compostos a serem utilizados em combinação para o tratamento de câncer
WO2010136491A1 (en) * 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
US8173650B2 (en) 2009-05-27 2012-05-08 Genentech, Inc. Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
BR112012000735A2 (pt) 2009-07-13 2016-11-16 Genentech Inc "métodos, kits e conjuntos de compostos"
US20120128670A1 (en) 2009-07-31 2012-05-24 OSI Pharmaceuticals, LLC mTOR INHIBITOR AND ANGIOGENESIS INHIBITOR COMBINATION THERAPY
JP2013503846A (ja) 2009-09-01 2013-02-04 ファイザー・インク ベンズイミダゾール誘導体
CN102597776A (zh) 2009-09-11 2012-07-18 霍夫曼-拉罗奇有限公司 鉴定响应抗癌剂的可能性升高的患者的方法
JP5606537B2 (ja) 2009-09-17 2014-10-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 癌患者における診断使用のための方法及び組成物
WO2011073521A1 (en) 2009-12-15 2011-06-23 Petri Salven Methods for enriching adult-derived endothelial progenitor cells and uses thereof
RS55487B2 (sr) 2010-02-12 2024-06-28 Pfizer Soli i polimorfi 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona
PH12012501693A1 (en) 2010-02-26 2012-11-05 Boehringer Ingelheim Int 4 - [cycloalkyloxy (hetero) arylamino] thieno [2,3 - d] pyrimidines having mnkl/mnk2 inhibiting activity for pharmaceutical compositions
UY33241A (es) 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
BR112012021453A2 (pt) 2010-02-26 2017-02-21 Boehringer Ingelheim Int tienopirimidina, sua composição farmacêutica e seu uso
AU2011223655A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2519826A2 (en) 2010-03-03 2012-11-07 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CN103038643A (zh) 2010-04-16 2013-04-10 基因泰克公司 作为pi3k/akt激酶途径抑制剂效能的预测性生物标记的foxo3a
CN102250112A (zh) * 2010-05-18 2011-11-23 上海再启生物技术有限公司 7-溴-4-氨基噻吩并嘧啶的制备方法
WO2011149126A1 (ko) * 2010-05-26 2011-12-01 한국과학기술연구원 타이로신 카이네이즈 저해능을 가지는 항염증 화합물을 포함하는 약학적 조성물
CN102971327B (zh) * 2010-05-26 2016-04-20 韩国科学技术研究院 具有多种酪氨酸激酶抑制活性的抗炎化合物以及含有这些化合物的药物组成物
WO2011153224A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
JP2013538042A (ja) 2010-06-16 2013-10-10 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション エンドプラスミンに対する抗体およびその使用
US20130225581A1 (en) 2010-07-16 2013-08-29 Kyowa Hakko Kirin Co., Ltd Nitrogen-containing aromatic heterocyclic derivative
BR112013001433A2 (pt) 2010-07-19 2016-05-31 Hoffmann La Roche método de identificação de pacientes com maior probabilidade de responder a terapia anticâncer
CN103109189A (zh) 2010-07-19 2013-05-15 霍夫曼-拉罗奇有限公司 鉴定响应抗癌疗法的可能性升高的患者的方法
WO2012012750A1 (en) 2010-07-23 2012-01-26 Trustees Of Boston University ANTI-DEsupR INHIBITORS AS THERAPEUTICS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS AND TUMOR CELL INVASIVENESS AND FOR MOLECULAR IMAGING AND TARGETED DELIVERY
EP2616441B1 (en) 2010-09-17 2019-08-07 Purdue Pharma L.P. Pyridine compounds and the uses thereof
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
WO2012052948A1 (en) 2010-10-20 2012-04-26 Pfizer Inc. Pyridine- 2- derivatives as smoothened receptor modulators
WO2012088254A1 (en) 2010-12-22 2012-06-28 Genentech, Inc. Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms
WO2012106522A2 (en) 2011-02-04 2012-08-09 Duquesne University Of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
US20140178368A1 (en) 2011-04-19 2014-06-26 Leslie Lynne SHARP Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
EP2734530A1 (en) 2011-07-19 2014-05-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PL3409278T3 (pl) 2011-07-21 2021-02-22 Sumitomo Pharma Oncology, Inc. Heterocykliczne inhibitory kinazy białkowej
MD20140023A2 (ro) 2011-09-22 2014-06-30 Pfizer Inc. Derivaţi de pirolpirimidină şi purină
AU2011378675B2 (en) 2011-10-04 2017-10-05 Epsilogen Ltd IgE anti -HMW-MAA antibody
CN103087077B (zh) * 2011-11-03 2016-05-18 上海希迈医药科技有限公司 噻吩并嘧啶和呋喃并嘧啶类衍生物、其制备方法及其在医药上的应用
RU2014114015A (ru) 2011-11-08 2015-12-20 Пфайзер Инк. Способы лечения воспалительных расстройств с использованием антител против m-csf
MX349548B (es) 2012-01-10 2017-08-02 Hoffmann La Roche Compuestos de tienopirimidina.
FR2988722B1 (fr) 2012-04-03 2014-05-09 Sanofi Sa Nouveaux derives de thienopyrimidines, leurs procedes de preparation et leurs utilisations therapeutiques
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
CN103360407B (zh) * 2012-04-10 2016-06-22 上海希迈医药科技有限公司 一种噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用
CN103664991B (zh) * 2012-09-19 2016-12-28 中国科学院福建物质结构研究所 噻吩[2,3‑d]嘧啶衍生物、其制备方法及其用途
WO2014062838A2 (en) 2012-10-16 2014-04-24 Tolero Pharmaceuticals, Inc. Pkm2 modulators and methods for their use
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
WO2014130923A2 (en) 2013-02-25 2014-08-28 Genentech, Inc. Methods and compositions for detecting and treating drug resistant akt mutant
RU2693480C2 (ru) 2013-03-14 2019-07-03 Толеро Фармасьютикалз, Инк. Ингибиторы jak2 и alk2 и способы их использования
US9206188B2 (en) 2013-04-18 2015-12-08 Arrien Pharmaceuticals Llc Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
TW201534597A (zh) * 2013-06-20 2015-09-16 Ab Science 作為選擇性蛋白質激酶抑制劑之苯并咪唑衍生物
CN105764511B (zh) 2013-10-04 2019-01-11 艾普托斯生物科学公司 用于治疗癌症的组合物和方法
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
PT3126521T (pt) 2014-04-04 2019-06-27 Crown Bioscience Inc Taicang Gene de fusão hnf4g-rspo2
WO2015155624A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. Dihydropyrrolopyrimidine derivatives
WO2015166373A1 (en) 2014-04-30 2015-11-05 Pfizer Inc. Cycloalkyl-linked diheterocycle derivatives
WO2016001789A1 (en) 2014-06-30 2016-01-07 Pfizer Inc. Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
BR112017000714A2 (pt) * 2014-07-16 2018-01-09 Novogen ltd indols funcionalizados e substituídos como agentes anti-câncer
ES2848857T3 (es) 2014-07-31 2021-08-12 Us Gov Health & Human Services Anticuerpos monoclonales humanos contra EphA4 y su uso
JP6621477B2 (ja) 2014-12-18 2019-12-18 ファイザー・インク ピリミジンおよびトリアジン誘導体ならびにａｘｌ阻害薬としてのそれらの使用
BR112017022666A8 (pt) 2015-04-20 2022-10-18 Tolero Pharmaceuticals Inc Preparando resposta à alvocidib por perfilamento mitocondrial
CN107709344B (zh) 2015-05-01 2022-07-15 共晶制药股份有限公司 用于治疗黄病毒科病毒和癌症的核苷类似物
CN111349118B (zh) 2015-05-18 2023-08-22 住友制药肿瘤公司 具有增加的生物利用度的阿伏西地前药
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
RU2759963C2 (ru) 2015-08-03 2021-11-19 Сумитомо Даиниппон Фарма Онколоджи, Инк. Комбинированные терапии для лечения рака
JP6877429B2 (ja) 2015-12-03 2021-05-26 アジオス ファーマシューティカルズ， インコーポレイテッド Ｍｔａｐヌル癌を処置するためのｍａｔ２ａ阻害剤
EP3394056B1 (en) 2015-12-22 2021-04-14 Shy Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
EP4001277A3 (en) * 2016-03-11 2022-09-14 AC Immune SA Bicyclic compounds for diagnosis and therapy
CN107652273B (zh) * 2016-07-26 2020-05-01 沈阳药科大学 嘧啶类衍生物及其制备方法和应用
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
JP6619519B2 (ja) 2016-12-19 2019-12-11 トレロ ファーマシューティカルズ， インコーポレイテッド プロファイリングペプチドおよび感受性プロファイリングのための方法
CA3066939A1 (en) 2017-06-21 2018-12-27 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
WO2019075367A1 (en) 2017-10-13 2019-04-18 Tolero Pharmaceuticals, Inc. PKM2 ACTIVATORS IN COMBINATION WITH OXYGEN REACTIVE SPECIES FOR THE TREATMENT OF CANCER
CA3103995A1 (en) 2018-07-26 2020-01-30 Sumitomo Dainippon Pharma Oncology, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
EP3883935A4 (en) * 2018-11-20 2022-08-10 Georgetown University COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE, MYODEGENERATIVE AND LYSOSOMA STORAGE DISEASES
MX2021006544A (es) 2018-12-04 2021-07-07 Sumitomo Pharma Oncology Inc Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
US12391705B2 (en) 2018-12-19 2025-08-19 Shy Therapeutics, Llc Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
TW202039481A (zh) 2018-12-21 2020-11-01 美商西建公司 Ripk2之噻吩并吡啶抑制劑
NZ778055A (en) 2019-02-12 2025-11-28 Sumitomo Pharma America Inc Formulations comprising heterocyclic protein kinase inhibitors
CA3129067A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
WO2020167624A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia
WO2020168927A1 (zh) * 2019-02-19 2020-08-27 四川科伦博泰生物医药股份有限公司 含氮并环化合物、其制备方法及用途
KR20210146287A (ko) * 2019-03-01 2021-12-03 레볼루션 메디슨즈, 인크. 이환식 헤테로아릴 화합물 및 이의 용도
JP2022525149A (ja) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
WO2020198077A1 (en) 2019-03-22 2020-10-01 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
WO2021057256A1 (zh) * 2019-09-29 2021-04-01 四川科伦博泰生物医药股份有限公司 一种含氮并环类化合物，包含其的药物组合物，其制备方法及其用途
WO2021118929A1 (en) * 2019-12-12 2021-06-17 Ptc Therapeutics, Inc. Compounds for treating familial dysautonomia
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof
CN115746017B (zh) * 2022-11-30 2024-06-07 英维沃化工科技(广州)有限公司 一种噻吩并嘧啶类化合物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0071227B1 (en) * 1981-07-31 1987-11-11 Sloan-Kettering Institute For Cancer Research Anti-leukemic beta-glycosyl c-nucleosides
EP0364598A4 (en) * 1988-03-02 1992-01-15 Yoshitomi Pharmaceutical Industries, Ltd. 3,4-dihydrothieno 2,3-d¨pyrimidine compounds and pharmaceutical application thereof
BR9101256A (pt) 1990-03-30 1991-11-05 Dowelanco Composto,composicao fungicida,processo fungicida,composicao inseticida ou acaricida e processo inseticida ou acaricida
US5187168A (en) 1991-10-24 1993-02-16 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
CA2129337A1 (en) * 1992-02-19 1993-09-02 Jotham W. Coe Heterocyclic compounds for enhancing antitumor activity
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
CA2223081C (en) * 1995-06-07 2001-03-06 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
AR004010A1 (es) * 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
ES2200039T3 (es) 1995-12-08 2004-03-01 Pfizer Inc. Derivados heterociclicos sustituidos como antagonistas de crf.
WO1997029110A1 (en) 1996-02-07 1997-08-14 Janssen Pharmaceutica N.V. Thiophenopyrimidines
ES2191187T3 (es) 1996-07-13 2003-09-01 Glaxo Group Ltd Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosin-quinasa.
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases

Also Published As

Publication number Publication date
TNSN98203A1 (fr) 2005-03-15
EP1028964A1 (en) 2000-08-23
BR9814018A (pt) 2000-09-26
HN1998000168A (es) 1999-01-08
MA24694A1 (fr) 1999-07-01
AP976A (en) 2001-06-12
IL135636A0 (en) 2001-05-20
CN1280580A (zh) 2001-01-17
ID23978A (id) 2000-06-14
AR018517A1 (es) 2001-11-28
EA005889B1 (ru) 2005-06-30
KR100446363B1 (ko) 2004-09-01
AU9454198A (en) 1999-05-31
HUP0100287A3 (en) 2003-04-28
MY132073A (en) 2007-09-28
CZ20001709A3 (cs) 2001-12-12
NO20002162D0 (no) 2000-04-27
HRP20000286A2 (en) 2000-12-31
JP2001522853A (ja) 2001-11-20
HUP0100287A2 (hu) 2001-09-28
UA72881C2 (uk) 2005-05-16
OA11376A (en) 2004-01-28
NZ520093A (en) 2004-03-26
EA200000391A1 (ru) 2000-12-25
PL340589A1 (en) 2001-02-12
SK6652000A3 (en) 2002-05-09
PA8462401A1 (es) 2000-05-24
TW593321B (en) 2004-06-21
GT199800180A (es) 2000-05-02
CO4990956A1 (es) 2000-12-26
AP9801389A0 (en) 1998-12-31
IS5464A (is) 2000-04-19
ZA9810253B (en) 2000-05-10
PE129099A1 (es) 1999-12-16
KR20010031908A (ko) 2001-04-16
BG104412A (en) 2001-02-28
BG65180B1 (bg) 2007-05-31
CA2309690A1 (en) 1999-05-20
CN101328186A (zh) 2008-12-24
US6492383B1 (en) 2002-12-10
UY25344A1 (es) 1999-09-27
DZ2646A1 (fr) 2003-03-15
UY25238A1 (es) 2000-12-29
WO1999024440A1 (en) 1999-05-20

Similar Documents

Publication Publication Date Title
NO20002162D0 (no) Tienopyrimidin- og tienopyridinderivater nyttige som anticancer midler
ATE260243T1 (de) N-aroylphenylalaninderivate
ATE235220T1 (de) Resorcinderivate
ID22781A (id) Turunan-turunan nikotinamida
NO20001631L (no) 2-metyl-tieno-benzodiazepin formulering
DK1930330T3 (da) Pleuromutilinderivater som antimikrobielle midler
DE69817186D1 (de) Diaminorhodamin-derivate
PT915088E (pt) Derivados de d-prolina
NO20000231D0 (no) Dolastatin-15-derivater
NO20000366D0 (no) O-substituerte hydroksycoumaranon-derivater som anti-tumor- og antimetastase-midler
DE69805807D1 (de) Mikrobiozide n-sulfonylglycin-alkynyloxyphenethylamid-derivate
DE69841086D1 (de) 5-Deoxy-Cytidin-Derivate
PT1027362E (pt) Derivados de cetolidos 2-halogeno-6-o-substituidos
PT869121E (pt) Derivados de propanolamina hipolipidemicos
DK0747346T3 (da) N-acyl-2-arylcyclopropylmethylaminderivater som melatonerge midler
DK0966437T3 (da) 5-Aroylnaphthalenderivater
EE200000061A (et) Värvaine
NO20003142L (no) Substituerte isokinolin-derivater og anvendelse derav som antikrampemidler
DE69829682D1 (de) Cis-disubstituierte aminocycloalkyl-pyrrolidin-derivate
NO981495L (no) Fenoksymetylpiperidin-derivater
NO20002321D0 (no) Bifenylderivater som farmasøytiske midler
DK1015447T3 (da) Piperidinylmethyloxazolidinonderivat
EP0998924A4 (en) ANTI-TUMOR ACTIVE
SE9704790D0 (sv) Vitaminkomposition
TR200000254A3 (tr) Antitümör ve antimetastaz maddeleri olarak O-ikameli hidroksikumaranon türevleri

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application